Barone Francesca 4

What Happened
Francesca Barone, Chief Scientific Officer of Candel Therapeutics (CADL), sold 23,447 shares on 2026-06-29. The reported weighted-average price was $10.06 per share, generating proceeds of about $235,769. The sale was effected pursuant to a 10b5-1 trading plan, which typically indicates a pre-arranged, automated sale rather than discretionary insider timing.

Key Details

• Transaction date: 2026-06-29 (reported on Form 4 filed 2026-07-01) — filing appears timely.
• Transaction type/code: Sale (S) — open market or private sale.
• Shares sold: 23,447; reported weighted-average price: $10.06; total proceeds: ~$235,769.
• Price range: shares were sold in multiple trades at prices between $10.00 and $10.14; the filing reports a weighted average and the filer can provide a breakdown on request (per footnote).
• Shares owned after transaction: Not disclosed in this filing.
• Notable footnotes: Transaction executed under a 10b5-1 plan adopted 2026-03-16 (pre-arranged plan).

Context
Because the sale was part of a 10b5-1 plan, it was pre-scheduled and is generally viewed as routine rather than a direct signal of the officer’s view on the company's near-term prospects. Sales are common for liquidity or diversification reasons; purchases are typically more informative about insider sentiment.